Abstract: Methods for producing phycotoxins from natural sources, wherein the phycotoxins have a definite compositional profile are described herein. In one embodiment, the phycotoxins are produced by cyanobacteria. In one embodiment, the phycotoxins are produced by continuously culturing cyanobacteria under strictly controlled conditions in order to produce a definite compositional profile. In another embodiment, organic nutrients are added to the culture that allows for higher concentrations of neosaxitoxin and saxitoxin or gonyaulatoxins 2 and 3 per weight of the algae. The phycotoxins are isolated primarily from the bacteria but can also be isolated from the culture medium. In one embodiment, the cyanobacteria produce only neosaxitoxin and saxitoxin in a ratio of about 6:1, 5:1, 4:1, or 3:1. In a preferred embodiment, the amount of saxitoxin is less than 20% by weight of the total amount of neosaxitoxin and saxitoxin produced. In another embodiment, the cyanobacteria produce only GTX2 and GTX 3.
Abstract: Power sources that enable in-body devices, such as implantable and ingestible devices, are provided. Aspects of the in-body power sources of the invention include a solid support, a first high surface area electrode and a second electrode. Embodiments of the in-power sources are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the power sources of the invention.
Type:
Grant
Filed:
February 14, 2008
Date of Patent:
February 17, 2015
Assignee:
Proteus Digital Health, Inc.
Inventors:
Hooman Hafezi, Timothy Robertson, Eric Snyder, Brad Cozad
Abstract: Methods, systems and compositions that allow for treating a patient according to a patient customized therapeutic regimen are provided. Embodiments of the invention include obtaining dosage administration information from a patient and using the same to tailor a therapeutic regimen for the patient. Embodiments of the invention further include preparing and forwarding to the patient physical pharmaceutical dosages based on the customized therapeutic regimen.
Type:
Grant
Filed:
May 2, 2007
Date of Patent:
February 17, 2015
Assignee:
Proteus Digital Health, Inc.
Inventors:
Mark J. Zdeblick, Andrew Thompson, George M. Savage
Abstract: Pharmaceutical delivery systems for delivering dosages according to the present invention include a carrier component and a cap configured to seal an internal volume of the carrier component, wherein the cap includes a device that produces a unique current signature. Dosages prepared to be delivered according to embodiments of the invention find use in a variety of different applications, including clinical trials.
Type:
Grant
Filed:
July 2, 2013
Date of Patent:
February 10, 2015
Assignee:
Proteus Digital Health, Inc.
Inventors:
Hooman Hafezi, Gregory Moon, Kityee Au-Yeung, Robert Duck, Maria Casillas Holen
Abstract: Phycotoxins are purified from a mixture of phycotoxins produced in a continuous process. Cyanobacteria are produced in a continuous culture, then lyzed, the cells pelleted and extracted, and the extract purified using an organic solvent-aqueous mixture and repeated passage through a diatomaceous earth column. The column is washed with acetic acid, then the neosaxitoxin extracted with an alcohol-water mixture. The eluate is passed through activated charcoal columns, which are washed with distilled water to remove the retained pigments and impurities, the further purified by HPLC. In one embodiment, the process produces only neosaxitoxin and saxitoxin. In another embodiment, the process produces only GTX2/3.
Abstract: Controlled activation identifiers for use in ingestible compositions, such as pharma-informatics enabled compositions, are provided. The identifiers include a controlled activation element that provides for activation of the identifier in response to the presence of a predetermined stimulus at a target site of interest. The invention finds use in a variety of different applications, including but not limited to, monitoring of therapeutic regimen compliance, tracking the history of pharmaceutical agents, etc.
Type:
Grant
Filed:
October 25, 2007
Date of Patent:
February 3, 2015
Assignee:
Proteus Digital Health, Inc.
Inventors:
Hooman Hafezi, Timothy Robertson, Olivier Colliou, Mark Zdeblick
Abstract: Multi-directional transmitters for in-body devices, such as implantable and ingestible devices, are provided. Aspects of the in-body multi-direction transmitters of the invention include signal transmitters configured to transmit an identifying signal in at least two different directions in an x-y plane. Embodiments of the in-body devices are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the devices of the invention.
Type:
Grant
Filed:
March 7, 2008
Date of Patent:
January 13, 2015
Assignee:
Proteus Digital Health, Inc.
Inventors:
Olivier Colliou, Timothy Robertson, Mark Zdeblick
Abstract: The system of the present invention includes a conductive element, an electronic component, and a partial power source in the form of dissimilar materials. Upon contact with a conducting fluid, a voltage potential is created and the power source is completed, which activates the system. The electronic component controls the conductance between the dissimilar materials to produce a unique current signature. The system can also measure the conditions of the environment surrounding the system.
Type:
Grant
Filed:
July 11, 2011
Date of Patent:
December 16, 2014
Assignee:
Proteus Digital Health, Inc.
Inventors:
Jeffrey Berkman, Mark Zdeblick, Patricia Johnson, Hooman Hafezi, Jonathan Withrington
Abstract: The invention provides a receiver associated with a body, e.g., located inside or within close proximity to a body, configured to receive and decode a signal from an in vivo transmitter which located inside the body. Signal receivers of the invention provide for accurate signal decoding of a low-level signal, even in the presence of significant noise, using a small-scale chip, e.g., where the chip consumes very low power. Also provided are systems that include the receivers, as well as methods of using the same.
Type:
Application
Filed:
March 6, 2014
Publication date:
November 13, 2014
Applicant:
Proteus Digital Health, Inc.
Inventors:
Lawrence Arne, Kit Yee Au-Yeung, Kenneth C. Crandall, Timothy Robertson
Abstract: A system for tracking a product from origin to destination is disclosed. The system includes a probe that comprises two plates, a power source and a processor. The power source is controlled by the processor to produce an oscillating output at the plates. Using the oscillating voltage, the probe interrogates a device through capacitive coupling. The device includes a control unit, a memory unit, and first and second materials physically associated with the device for communication using capacitive coupling. Information associated with the device is transferred from the device to the probe through capacitive coupling between the first and second materials and the first and second plates, respectively.
Abstract: Virtual dipole signal amplification for in-body devices, such as implantable and ingestible devices, is provided. Aspects of the in-body deployable antennas of the invention include antennas configured to go from a first configuration to a second configuration following placement in a living body, e.g., via ingestion or implantation. Embodiments of the in-body devices are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the devices of the invention.
Type:
Application
Filed:
January 22, 2014
Publication date:
October 16, 2014
Applicant:
Proteus Digital Health, Inc.
Inventors:
Hooman Hafezi, Benedict Costello, Timothy Robertson, Maria Casillas Holen
Abstract: Ingestible event marker systems that include an ingestible event marker (i.e., an IEM) and a personal signal receiver are provided. Embodiments of the IEM include an identifier, which may or may not be present in a physiologically acceptable carrier. The identifier is characterized by being activated upon contact with a target internal physiological site of a body, such as digestive tract internal target site. The personal signal receiver is configured to be associated with a physiological location, e.g., inside of or on the body, and to receive a signal the IEM. During use, the IEM broadcasts a signal which is received by the personal signal receiver.
Type:
Grant
Filed:
February 1, 2008
Date of Patent:
October 14, 2014
Assignee:
Proteus Digital Health, Inc.
Inventors:
Timothy Robertson, George Savage, Mark Zdeblick, Yashar Behzadi, Benedict Costello, Jeremy Frank, Hooman Hafezi, Tariq Haniff, David O'Reilly
Abstract: Compositions, systems and methods that allow for the detection of the actual physical delivery of a pharmaceutical agent to a body are provided. Embodiments of the compositions include an identifier and an active agent. The invention finds use in a variety of different applications, including but not limited to, monitoring of therapeutic regimen compliance, tracking the history of pharmaceutical agents, etc.
Type:
Grant
Filed:
April 28, 2006
Date of Patent:
September 30, 2014
Assignee:
Proteus Digital Health, Inc.
Inventors:
Mark Zdeblick, Andrew Thompson, Aleksandr Pikelny, Timothy Robertson, Hooman Hafezi
Abstract: The system of the present invention includes a conductive element, an electronic component, and a partial power source in the form of dissimilar materials. Upon contact with a conducting fluid, a voltage potential is created and the power source is completed, which activates the system. The electronic component controls the conductance between the dissimilar materials to produce a unique current signature. The system can also be associated with food and communicate data about ingestion of food material to a receiver.
Abstract: The system of the present invention includes a conductive element, an electronic component, and a partial power source in the form of dissimilar materials. Upon contact with a conducting fluid, a voltage potential is created and the power source is completed, which activates the system. The electronic component controls the conductance between the dissimilar materials to produce a unique current signature. The system can be used in a variety of different applications, including as components of ingestible identifiers, such as may be found in ingestible event markers, e.g., pharma-informatics enabled pharmaceutical compositions.
Type:
Grant
Filed:
June 3, 2011
Date of Patent:
August 26, 2014
Assignee:
Proteus Digital Health, Inc.
Inventors:
Mark Zdeblick, Timothy Robertson, Aleksandr Pikelny, Hooman Hafezi
Abstract: Receivers, which may be external or implantable, are provided. Aspects of receivers of the invention include the presence of one or more of: a high power-low power module; an intermediary module; a power supply module configured to activate and deactivate one or more power supplies to a high power processing block; a serial peripheral interface bus connecting master and slave blocks; and a multi-purpose connector. Receivers of the invention may be configured to receive a conductively transmitted signal. Also provided are systems that include the receivers, as well as methods of using the same. Additionally systems and methods are disclosed for using a receiver for coordinating with dosage delivery systems.
Type:
Application
Filed:
April 30, 2013
Publication date:
August 21, 2014
Applicant:
Proteus Digital Health, Inc
Inventors:
Timothy L. Robertson, Fataneh Omidvar, Yashar Behzadi, Lawrence Arne, Kenneth Rowberry, James Hutchison, Robert Leichner, George Savage, Andrew Thompson, Mark Zdeblick, Marc Kreidler, Hooman Hafezi, Robert Duck